Elanco Animal Health Incorporated $ELAN Shares Acquired by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. increased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 1,222.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 83,853 shares of the company’s stock after buying an additional 77,510 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Elanco Animal Health were worth $1,898,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Legacy Capital Group California Inc. increased its stake in shares of Elanco Animal Health by 3.1% during the fourth quarter. Legacy Capital Group California Inc. now owns 20,988 shares of the company’s stock worth $475,000 after buying an additional 632 shares during the period. AlphaQuest LLC increased its stake in shares of Elanco Animal Health by 13.7% during the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock worth $120,000 after buying an additional 718 shares during the period. Jones Financial Companies Lllp increased its stake in shares of Elanco Animal Health by 15.2% during the third quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock worth $119,000 after buying an additional 798 shares during the period. US Bancorp DE increased its stake in shares of Elanco Animal Health by 1.9% during the third quarter. US Bancorp DE now owns 43,810 shares of the company’s stock worth $882,000 after buying an additional 824 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in shares of Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after buying an additional 900 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $23.71 on Thursday. The firm has a market capitalization of $11.84 billion, a P/E ratio of -47.41, a P/E/G ratio of 2.46 and a beta of 1.69. Elanco Animal Health Incorporated has a 52 week low of $12.97 and a 52 week high of $27.72. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The firm’s 50 day moving average is $23.00 and its two-hundred day moving average is $23.30.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm’s revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. UBS Group restated a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. KeyCorp upped their target price on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Leerink Partners upped their target price on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 24th. Finally, JPMorgan Chase & Co. upped their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.20.

Insider Activity at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction on Friday, May 15th. The shares were bought at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Rajeev A. Modi purchased 4,911 shares of the company’s stock in a transaction on Friday, May 15th. The stock was bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 1.14% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.